Agilent Technologies (NYSE:A) Price Target Lowered to $150.00 at Bank of America

Agilent Technologies (NYSE:A) had its price target decreased by research analysts at Bank of America from $153.00 to $150.00 in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Bank of America‘s price objective suggests a potential upside of 7.91% from the company’s previous close.

Several other research firms have also recently issued reports on A. Stifel Nicolaus reissued a “buy” rating and issued a $151.00 target price on shares of Agilent Technologies in a research note on Monday, August 26th. Barclays cut their price objective on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 27th. UBS Group upped their target price on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. StockNews.com cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, November 26th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $143.62.

Agilent Technologies Trading Down 1.4 %

Shares of A stock opened at $139.00 on Friday. The business has a 50-day moving average price of $136.75 and a two-hundred day moving average price of $136.44. Agilent Technologies has a 12-month low of $124.16 and a 12-month high of $155.35. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57. The firm has a market cap of $39.94 billion, a P/E ratio of 31.45, a price-to-earnings-growth ratio of 4.48 and a beta of 1.07.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.05. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The business had revenue of $1.70 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same period in the prior year, the business posted $1.38 earnings per share. The company’s revenue was up .8% on a year-over-year basis. Equities analysts anticipate that Agilent Technologies will post 5.56 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. This represents a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.33% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Agilent Technologies

A number of hedge funds have recently bought and sold shares of the company. Assenagon Asset Management S.A. boosted its stake in Agilent Technologies by 2.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 9,910 shares of the medical research company’s stock valued at $1,285,000 after purchasing an additional 226 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Agilent Technologies by 331.6% during the second quarter. Blue Trust Inc. now owns 4,148 shares of the medical research company’s stock valued at $538,000 after buying an additional 3,187 shares during the last quarter. Brookstone Capital Management increased its holdings in Agilent Technologies by 14.9% in the 2nd quarter. Brookstone Capital Management now owns 1,698 shares of the medical research company’s stock worth $227,000 after buying an additional 220 shares in the last quarter. Gradient Investments LLC raised its position in Agilent Technologies by 196.1% in the 2nd quarter. Gradient Investments LLC now owns 832 shares of the medical research company’s stock worth $108,000 after buying an additional 551 shares during the last quarter. Finally, Marshall Financial Group LLC bought a new position in Agilent Technologies during the 2nd quarter valued at about $1,058,000. Institutional investors own 87.42% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.